Unlocking the Potential of Electronic Health Records for Rare Disease Trials

Why Electronic Health Records Matter in Rare Disease Research

Identifying eligible patients for rare disease clinical trials is one of the greatest barriers in orphan drug development. Unlike common diseases with large patient databases, rare disease patients are often scattered across different health systems, misdiagnosed, or not tracked consistently. Electronic Health Records (EHRs) provide a powerful solution by aggregating longitudinal patient data across healthcare providers, enabling more efficient identification of trial candidates.

EHRs store structured information such as demographics, diagnoses, lab values, and prescriptions, along with unstructured data like physician notes. Mining this data with advanced informatics tools allows researchers to detect phenotypic signatures, uncover undiagnosed patients, and assess trial feasibility. This approach reduces screening costs, improves enrollment speed, and enhances trial representativeness.

Global regulatory bodies, including the U.S. National Clinical Trials Registry, emphasize the use of real-world data sources like EHRs in trial design and recruitment strategies. Leveraging EHRs thus aligns with both operational and regulatory priorities.

Approaches to Mining EHR Data

Mining EHRs for rare disease trials involves multiple techniques tailored to structured and unstructured data:

• Structured Querying: Using ICD-10 codes, lab results, and medication histories to filter patient populations. For instance, elevated creatine kinase (CK) levels combined with muscle weakness codes may suggest muscular dystrophy.
• Natural Language Processing (NLP): Analyzing unstructured clinical notes to extract disease-specific terms, family histories, or symptom clusters not captured in structured fields.
• Phenotype Algorithms: Creating phenotype risk scores by integrating multiple data points such as lab abnormalities, genetic test results, and prescription histories.
• Predictive Analytics: Applying machine learning to predict undiagnosed cases based on subtle symptom patterns.

For example, in a rare metabolic disorder trial, a predictive algorithm might identify candidates by analyzing abnormal LOD/LOQ thresholds in lab data combined with narrative evidence of progressive fatigue in physician notes.

Case Study: EHR Mining in Cystic Fibrosis

Cystic fibrosis (CF) is a rare genetic condition with well-established diagnostic markers. A major U.S. academic center used EHR mining across regional hospitals to identify undiagnosed or misclassified patients. By combining ICD-10 codes with sweat chloride levels, genetic tests, and keyword mentions in clinician notes, the algorithm identified 40 additional patients who were later confirmed through genetic testing. These patients were successfully recruited into a Phase III CFTR modulator trial, accelerating enrollment by nearly 30% compared to traditional methods.

Regulatory and Data Privacy Challenges

Mining EHRs comes with complex compliance challenges:

• HIPAA and GDPR Compliance: Patient data must be anonymized or de-identified before being used for recruitment, ensuring that only authorized parties access identifiable information.
• Institutional Review Board (IRB) Approval: Studies involving secondary use of EHR data must be reviewed and approved by IRBs to safeguard ethical standards.
• Interoperability Issues: Different hospitals use different EHR platforms, often lacking standardized coding, which complicates large-scale data aggregation.
• Bias and Representation: Over-reliance on EHR data from specific centers may result in underrepresentation of minority or rural patients.

To overcome these issues, sponsors increasingly adopt federated data networks that allow analysis of EHR data across multiple institutions without direct data sharing.

Dummy Data Example for Rare Disease EHR Mining

The following table demonstrates a simplified view of EHR mining outputs for a hypothetical rare neuromuscular disorder:

Integration with Recruitment Workflows

Once candidates are flagged by EHR mining, integration into recruitment workflows is essential. Trial coordinators receive alerts via CTMS dashboards, and physicians are prompted to discuss potential trial enrollment during routine visits. Automated pre-screening forms linked to EHR data further reduce site workload, ensuring only eligible patients are contacted.

Such integration not only accelerates enrollment but also improves patient trust, since trial offers are framed as part of ongoing care rather than unsolicited outreach.

Future Directions: AI and Real-World Evidence

The future of EHR mining lies in combining AI-driven analysis with real-world evidence generation. Natural language processing will refine patient stratification, while machine learning models may predict disease trajectories, supporting adaptive trial designs. By integrating genomic data with EHR mining, sponsors will also identify patients with specific mutations, enabling precision recruitment for gene therapy trials.

As rare disease research evolves, EHR mining will shift from being a recruitment tool to a broader platform supporting feasibility assessments, endpoint validation, and long-term post-marketing surveillance.

Conclusion

Mining electronic health records is transforming rare disease clinical research by making patient identification faster, cheaper, and more accurate. While regulatory, privacy, and interoperability challenges remain, advances in AI, federated networks, and NLP are overcoming these barriers. Sponsors who harness EHR data effectively will gain a competitive edge in orphan drug development, accelerating the journey from bench to bedside for underserved patient populations.

Therapeutic Area Registries Around the World: Practical Examples for Real-World Evidence

Therapeutic area registries are pivotal tools for tracking real-world treatment outcomes, understanding disease progression, and supporting regulatory decisions. Around the globe, registries have been established in diverse therapeutic domains—from oncology and cardiology to rare and autoimmune diseases. This guide showcases global examples of therapeutic area registries, providing pharma and clinical trial professionals with actionable insights into structure, success factors, and real-world evidence (RWE) contributions.

Why Therapeutic Registries Matter:

Unlike clinical trials, therapeutic registries reflect broad patient populations, treatment heterogeneity, and healthcare system variations. They help:

• Assess long-term treatment effectiveness and safety
• Identify unmet needs in patient care
• Support market access and reimbursement decisions
• Fulfill post-marketing regulatory obligations

Well-designed registries often align with pharma regulatory compliance expectations and can even act as external control arms for clinical studies.

1. Cardiovascular Registries:

Example: SWEDEHEART (Sweden)

• Focus: Acute coronary syndromes, heart failure, and interventions
• Scope: National registry linking hospitals, labs, and pharmacies
• Impact: Improved adherence to guidelines and reduced mortality

SWEDEHEART demonstrates how integrated EHR-based data collection and continuous quality feedback can transform outcomes.

2. Oncology Registries:

Example: SEER Program (United States)

• Focus: Cancer incidence, survival, treatment trends
• Scope: Covers 48% of the U.S. population across multiple states
• Impact: Enables survival trend analysis and population-based outcome research

SEER data is frequently used to inform GMP audit checklist-aligned pharmacovigilance programs and comparative effectiveness research.

3. Autoimmune Disease Registries:

Example: British Society for Rheumatology Biologics Register (BSRBR)

• Focus: Safety and effectiveness of biologic therapies in rheumatoid arthritis
• Scope: More than 20,000 patients enrolled in the UK
• Impact: Helped identify infection and malignancy risks linked to biologics

The BSRBR registry supports long-term risk-benefit profiling of immune-modulating therapies and aligns with principles seen on StabilityStudies.in.

4. Diabetes Registries:

Example: DPV Initiative (Germany)

• Focus: Pediatric and adult patients with type 1 and type 2 diabetes
• Scope: Multinational data from over 400 centers in Europe
• Impact: Improved glycemic control, therapy standardization, and benchmarking

DPV exemplifies how structured data collection combined with feedback to providers can drive measurable care improvements.

5. Rare Disease Registries:

Example: Cystic Fibrosis Foundation Patient Registry (CFFPR – USA)

• Focus: Tracking health outcomes in cystic fibrosis (CF)
• Scope: >30,000 patients across 130 accredited care centers
• Impact: Data used to support FDA approvals and improve median life expectancy

Rare disease registries are essential when randomized trials are infeasible. They require adherence to equipment qualification for data systems due to their regulatory utility.

6. Neurological Disease Registries:

Example: MSBase (Global)

• Focus: Long-term outcomes in multiple sclerosis (MS)
• Scope: Over 70,000 patients in 40+ countries
• Impact: Enables global tracking of treatment switches, relapses, and disability progression

MSBase uses a harmonized data model and governance framework to allow cross-border data sharing.

7. Orthopedic and Surgical Registries:

Example: Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR)

• Focus: Joint replacement outcomes and device surveillance
• Scope: Nationwide registry capturing >98% of all procedures
• Impact: Identified underperforming implants and led to regulatory actions

This registry supports proactive safety signal detection and aligns with post-market surveillance requirements set by TGA.

8. Pediatric Registries:

Example: PEDSnet (United States)

• Focus: Learning health system for pediatric populations
• Scope: Data from eight children’s hospitals across the U.S.
• Impact: Accelerated observational studies, registry-based trials, and QI programs

PEDSnet uses standardized terminologies and centralized governance to ensure reproducibility and security.

Lessons from Global Registries:

• Strong governance: Define oversight boards, publication policies, and data access rules
• Data interoperability: Use HL7 FHIR, CDISC, and MedDRA standards
• Electronic systems: Ensure systems are validated for security and auditability, per SOP training pharma guidelines
• Participant engagement: Transparency and feedback loops improve retention
• Multistakeholder collaboration: Involve payers, regulators, clinicians, and patients

How to Apply These Models to New Registries:

Pharma professionals launching new registries can take inspiration from global examples by:

1. Defining precise therapeutic and geographic scope
2. Benchmarking data elements and follow-up intervals
3. Incorporating quality-of-life and adherence metrics
4. Establishing shared governance with local investigators
5. Aligning with real-world regulatory standards and practices

Conclusion:

Therapeutic area registries from around the world offer practical blueprints for successful real-world evidence generation. By understanding how global leaders structure and sustain their registries, pharma professionals can design programs that not only meet scientific and regulatory expectations but also drive lasting improvements in patient care. Whether tracking rare diseases or chronic conditions, registries remain foundational to data-driven healthcare decisions across the globe.